Anjali Ganguli

Corporate Officer/Principal presso SYNDAX PHARMACEUTICALS, INC.

48 anni

Health Technology

Consumer Services

Posizioni attive di Anjali Ganguli

Società	Posizione	Inizio	Fine
SYNDAX PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/05/2015	-

Società	Posizione	Inizio	Fine
Regado Biosciences, Inc. Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ.	Corporate Officer/Principal	01/02/2014	01/05/2015

University of Michigan	Doctorate Degree
The University of Chicago	Undergraduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Corporate Officer/Principal	2
Doctorate Degree	1
Undergraduate Degree	1

Settori

Health Technology	3
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
SYNDAX PHARMACEUTICALS, INC.	Health Technology

Aziende private	1
Regado Biosciences, Inc. Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ.	Health Technology

Aziende private

Health Technology